DHR vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DHR and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DHR | RGC |
|---|---|---|
| Company Name | Danaher Corporation | Regencell Bioscience Holdings Limited |
| Country | United States | Hong Kong |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 158.33 billion USD | 6.35 billion USD |
| Exchange | NYSE | NasdaqCM |
| Listing Date | December 29, 1978 | July 16, 2021 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DHR and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DHR | RGC |
|---|---|---|
| 5-Day Price Return | 4.75% | -8.89% |
| 13-Week Price Return | 4.87% | -3.96% |
| 26-Week Price Return | 12.51% | 53.28% |
| 52-Week Price Return | -8.41% | 7,311.76% |
| Month-to-Date Return | 2.71% | -24.32% |
| Year-to-Date Return | -3.63% | 9,592.31% |
| 10-Day Avg. Volume | 3.63M | 0.13M |
| 3-Month Avg. Volume | 4.17M | 0.32M |
| 3-Month Volatility | 31.75% | 89.95% |
| Beta | 0.90 | 2.34 |
Profitability
Return on Equity (TTM)
DHR
6.88%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
DHR’s Return on Equity of 6.88% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DHR
14.43%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
DHR’s Net Profit Margin of 14.43% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
RGC
--
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
DHR
19.05%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
DHR’s Operating Profit Margin of 19.05% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
RGC
--
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
| Symbol | DHR | RGC |
|---|---|---|
| Return on Equity (TTM) | 6.88% | -54.75% |
| Return on Assets (TTM) | 4.40% | -51.38% |
| Net Profit Margin (TTM) | 14.43% | -- |
| Operating Profit Margin (TTM) | 19.05% | -- |
| Gross Profit Margin (TTM) | 59.59% | -- |
Financial Strength
Current Ratio (MRQ)
DHR
1.52
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
DHR’s Current Ratio of 1.52 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
RGC
42.68
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RGC
0.00
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
| Symbol | DHR | RGC |
|---|---|---|
| Current Ratio (MRQ) | 1.52 | 42.68 |
| Quick Ratio (MRQ) | 0.98 | 41.89 |
| Debt-to-Equity Ratio (MRQ) | 0.33 | 0.00 |
| Interest Coverage Ratio (TTM) | 22.31 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DHR
0.54%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.54% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
DHR
24.18%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 24.18% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DHR | RGC |
|---|---|---|
| Dividend Yield (TTM) | 0.54% | 0.00% |
| Dividend Payout Ratio (TTM) | 24.18% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DHR
44.62
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
DHR’s P/E Ratio of 44.62 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RGC
--
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
DHR
6.44
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
DHR’s P/S Ratio of 6.44 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
RGC
--
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
DHR
2.59
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
DHR’s P/B Ratio of 2.59 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | DHR | RGC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 44.62 | -- |
| Price-to-Sales Ratio (TTM) | 6.44 | -- |
| Price-to-Book Ratio (MRQ) | 2.59 | 9.57 |
| Price-to-Free Cash Flow Ratio (TTM) | 31.16 | -- |